SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/7EDB808F431388190DC9759378EA07DA70C3BA6CF47065BEA1675D620C5E1672F927C403A7E470805FFE9EEE0EA3F805>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/7EDB808F431388190DC9759378EA07DA70C3BA6CF47065BEA1675D620C5E1672F927C403A7E470805FFE9EEE0EA3F805
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/7EDB808F431388190DC9759378EA07DA70C3BA6CF47065BEA1675D620C5E1672F927C403A7E470805FFE9EEE0EA3F805
http://www.w3.org/2000/01/rdf-schema#comment
"Possession of the CYP2C9*2 or CYP2C9*3 variant alleles results in decreased enzyme activity and has been associated with a significant decrease in mean warfarin dose requirements."
xsd:string
http://purl.uniprot.org/uniprot/#_E1183FFF1AFF6FBF32E50A25FD67F63AEBBC4248EC7E856D7B761149A5BE6410334CBE453E9E2D5D1EFA43B35E49752F
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/7EDB808F431388190DC9759378EA07DA70C3BA6CF47065BEA1675D620C5E1672F927C403A7E470805FFE9EEE0EA3F805
http://purl.uniprot.org/uniprot/S5RV20
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/7EDB808F431388190DC9759378EA07DA70C3BA6CF47065BEA1675D620C5E1672F927C403A7E470805FFE9EEE0EA3F805
http://purl.uniprot.org/uniprot/#_S5RV20-mappedCitation-15199455
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/7EDB808F431388190DC9759378EA07DA70C3BA6CF47065BEA1675D620C5E1672F927C403A7E470805FFE9EEE0EA3F805